Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

July 1, 2021

Study Completion Date

August 28, 2021

Conditions
Glioblastoma or Malignant Glioma
Interventions
DRUG

AMG 596

Drug

DRUG

AMG 404

Drug

Trial Locations (10)

2065

Royal North SHore Hospital, St Leonards

3000

Peter MacCallum Cancer Centre, Melbourne

10065

Memorial Sloan Kettering Cancer Center, New York

20246

Universitatsklinikum Hamburg-Eppendorf, Hamburg

90024

University of California Los Angeles, Los Angeles

94800

Gustave Roussy, Villejuif

97080

Universitaetsklinikum Wuerzburg, Würzburg

01307

Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden

1081 HV

Vrije Universiteit Medisch Centrum, Amsterdam

08916

Hospital Universitari Germans Trias i Pujol, Badalona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03296696 - Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma | Biotech Hunter | Biotech Hunter